Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

NCT04989621 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma
Relapsed and Refractory Follicular Lymphoma

Interventions

DRUG: Orelabrutinib and Rituximab
DRUG: Orelabrutinib

Sponsor

Sun Yat-sen University